{"nctId":"NCT01229371","briefTitle":"Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers","startDateStruct":{"date":"2010-10"},"conditions":["Influenza"],"count":440,"armGroups":[{"label":"Subjects ≥18 to ≤60 Years - CSL HA Antigen","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Inflexal V influenza vaccine (CSL HA Antigen) 2010"]},{"label":"Subjects >60 Years - CSL HA Antigen","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Inflexal V influenza vaccine (CSL HA Antigen) 2010"]},{"label":"Subjects ≥18 to ≤60 Years - AdImmune HA Antigen","type":"EXPERIMENTAL","interventionNames":["Biological: Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011"]},{"label":"Subjects >60 Years - AdImmune HA Antigen","type":"EXPERIMENTAL","interventionNames":["Biological: Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011"]}],"interventions":[{"name":"Inflexal V influenza vaccine (CSL HA Antigen) 2010","otherNames":[]},{"name":"Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy female and male adults\n* Aged ≥18 years on Day 1\n* Written informed consent\n\nExclusion Criteria:\n\n* Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease\n* Acute febrile illness (≥38.0 °C)\n* Prior vaccination with an influenza vaccine (including the H1N1 pandemic swine flu vaccine) in the past 330 days\n* Known hypersensitivity to any vaccine component\n* Previous history of a serious adverse reaction to influenza vaccine\n* History of egg protein allergy or severe atopy\n* Known blood coagulation disorder\n* Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, incl. oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent (inhaled or topical steroids are allowed)\n* Known immunodeficiency (incl. leukemia, cancer, HIV seropositivity)\n* Investigational medicinal product received in the past 3 months (90 days)\n* Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days)\n* Pregnancy or lactation\n* Participation in another clinical trial\n* Employee at the investigational site, or spouse and children of the investigator, or relative living in the same household as the investigator and/or are dependent on the investigator\n* Suspected non-compliance","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity - Geometric Mean Titer Fold Increase From Baseline","description":"The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA \"Note for guidance on harmonisation of requirements for influenza vaccines,\" 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"4.5","spread":null},{"groupId":"OG003","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"2.2","spread":null},{"groupId":"OG003","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"3.1","spread":null},{"groupId":"OG002","value":"1.9","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Local and Systemic Adverse Events","description":"Solicited local and systemic AEs, Unsolicited AEs, Tolerability and acceptability\n\nUnsolicited AEs were collected from baseline (Day 1) to 3 weeks after vaccination (Day 22 ± 2 days).\n\nSolicited local and systemic AEs were collected by subjects diary from Day 1 (day of vaccination) to Day 4","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity - Seroprotection Rate","description":"The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA \"Note for guidance on harmonisation of requirements for influenza vaccines,\" 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"98.2","spread":null},{"groupId":"OG002","value":"92.7","spread":null},{"groupId":"OG003","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null},{"groupId":"OG001","value":"97.3","spread":null},{"groupId":"OG002","value":"85.5","spread":null},{"groupId":"OG003","value":"86.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity - Seroconversion Rate","description":"The primary endpoints were the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA \"Note for guidance on harmonisation of requirements for influenza vaccines,\" 1997 and they were the following: 1. Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40, 2. Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40, 3. GMT of HI antibodies and fold-increase in GMT","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"52.7","spread":null},{"groupId":"OG002","value":"54.5","spread":null},{"groupId":"OG003","value":"43.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":null},{"groupId":"OG001","value":"29.1","spread":null},{"groupId":"OG002","value":"25.5","spread":null},{"groupId":"OG003","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":null},{"groupId":"OG001","value":"44.5","spread":null},{"groupId":"OG002","value":"20.9","spread":null},{"groupId":"OG003","value":"20.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":["Pain (at the injection site)","Induration (at the injection site)","Erythema (at the injection site)","Malaise","Chills"]}}}